{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:55:51Z","timestamp":1789638951493,"version":"4.0.0"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of the Witwatersrand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This paper provides an expert review of extant research into commercially utilized targeted drug delivery systems for brain therapeutics, with Glioblastoma Multiforme (GBM), Parkinson\u2019s Disease (PD), Alzheimer\u2019s Disease (AD) and Major Depressive Disorder (MDD), as case studies. While the paper highlights the progress made in developing effective drug delivery solutions, a common denominator across much of the research is the singular challenge posed by the Blood Brain Barrier (BBB) against the bulk of drug delivery options and treatments. The paper identifies critical pathways and transporting effective therapeutics through the barrier, and calls for further innovation into nano-systems, gels, and wafers with BBB-beating properties. The paper calls for the modernization of manufacturing regulatory systems, as well as increased preclinical studies and clinical trials to establish the utility of such nano-systems. Ultimately, the paper vouches for fast-tracking and even exemption of promising delivery solutions from phase IV studies but instead to accurately assess and evaluate the solutions' efficacy in a \u201creal\u00a0world\"\u00a0setting.<\/jats:p>","DOI":"10.1208\/s12249-026-03386-7","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T21:31:36Z","timestamp":1772659896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-8163","authenticated-orcid":false,"given":"Brian Timothy","family":"Kariithi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8640-4350","authenticated-orcid":false,"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-1529","authenticated-orcid":false,"given":"Yahya Essop","family":"Choonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"3386_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","volume":"19","author":"VL Feigin","year":"2020","unstructured":"Feigin VL, et al. The global burden of neurological disorders: translating evidence into policy. Policy View Lancet Neurol. 2020;19:255\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(19)30411-9.","journal-title":"Policy View Lancet Neurol"},{"issue":"7","key":"3386_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2023.E18222","volume":"9","author":"I Ilic","year":"2023","unstructured":"Ilic I, Ilic M. International patterns and trends in the brain cancer incidence and mortality: an observational study based on the global burden of disease. Heliyon. 2023;9(7):e18222. https:\/\/doi.org\/10.1016\/J.HELIYON.2023.E18222.","journal-title":"Heliyon"},{"issue":"2","key":"3386_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2217\/nnm-2019-0367","volume":"15","author":"JJ Mulvihill","year":"2020","unstructured":"Mulvihill JJ, Cunnane EM, Ross AM, Duskey JT, Tosi G, Grabrucker AM. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers. Nanomedicine. 2020;15(2):205\u201314. https:\/\/doi.org\/10.2217\/nnm-2019-0367.","journal-title":"Nanomedicine"},{"key":"3386_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.ADDR.2019.11.009","volume":"165","author":"R Pandit","year":"2020","unstructured":"Pandit R, Chen L, G\u00f6tz J. The blood-brain barrier: physiology and strategies for drug delivery. Adv Drug Deliv Rev. 2020;165:1\u201314. https:\/\/doi.org\/10.1016\/J.ADDR.2019.11.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"3386_CR5","doi-asserted-by":"publisher","unstructured":"Dong X. Current strategies for brain drug delivery. Ivyspring International Publisher. 2018. https:\/\/doi.org\/10.7150\/thno.21254.","DOI":"10.7150\/thno.21254"},{"key":"3386_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11050245","author":"A Parodi","year":"2019","unstructured":"Parodi A, Rudzi\u0144ska M, Deviatkin AA, Soond SM, Baldin AV, Zamyatnin AA. Established and emerging strategies for drug delivery across the blood-brain barrier in brain cancer. Pharmaceutics. 2019. https:\/\/doi.org\/10.3390\/pharmaceutics11050245.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3386_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1021\/acs.chemmater.2c03003","volume":"35","author":"J Gao","year":"2023","unstructured":"Gao J, Karp JM, Langer R, Joshi N. The future of drug delivery. Chem Mater. 2023;35(2):359\u201363. https:\/\/doi.org\/10.1021\/acs.chemmater.2c03003.","journal-title":"Chem Mater"},{"key":"3386_CR8","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2019-0130","author":"R Bosetti","year":"2019","unstructured":"Bosetti R, Jones SL, Future Medicine Ltd. Cost-effectiveness of nanomedicine: estimating the real size of nano-costs. Nanomedicine. 2019. https:\/\/doi.org\/10.2217\/nnm-2019-0130.","journal-title":"Nanomedicine"},{"key":"3386_CR9","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S313968","author":"A Tewabe","year":"2021","unstructured":"Tewabe A, Abate A, Tamrie M, Seyfu A, Siraj EA, Dove Medical Press Ltd. Targeted drug delivery \u2014 from magic bullet to nanomedicine: principles, challenges, and future perspectives. J Multidiscip Healthc. 2021. https:\/\/doi.org\/10.2147\/JMDH.S313968.","journal-title":"J Multidiscip Healthc"},{"key":"3386_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.952161","author":"C Ding","year":"2022","unstructured":"Ding C, et al. Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990\u20132019. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2022.952161.","journal-title":"Front Public Health"},{"issue":"4","key":"3386_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344\u201381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3.","journal-title":"Lancet Neurol"},{"key":"3386_CR12","unstructured":"Global Burden of Disease Collaborative Network, Global Burden of Disease Study 2021 (GBD 2021) Results, Seattle, US, 2022. [Online]. Available: https:\/\/vizehub.healthdata.org\/gbd-results\/"},{"issue":"10","key":"3386_CR13","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):e551\u201367. https:\/\/doi.org\/10.1016\/S2468-2667(20)30190-0.","journal-title":"Lancet Public Health"},{"issue":"1","key":"3386_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/S-0040-1712606","volume":"52","author":"RK Chadda","year":"2020","unstructured":"Chadda RK, Chadda RK. Global burden of mental disorders: meeting the challenge. Ann Natl Acad Med Sci. 2020;52(1):39\u201355. https:\/\/doi.org\/10.1055\/S-0040-1712606.","journal-title":"Ann Natl Acad Med Sci"},{"issue":"2","key":"3386_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"A Ferrari","year":"2022","unstructured":"Ferrari A. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137\u201350. https:\/\/doi.org\/10.1016\/S2215-0366(21)00395-3.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"3386_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137\u201350. https:\/\/doi.org\/10.1016\/S2215-0366(21)00395-3.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"3386_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8(1):1\u201327. https:\/\/doi.org\/10.1038\/s41392-023-01481-w.","journal-title":"Signal Transduct Target Ther"},{"key":"3386_CR18","doi-asserted-by":"publisher","DOI":"10.15586\/codon.glioblastoma.2017.ind","volume-title":"Glioblastoma","year":"2017","unstructured":"De Vleeschouwer S, editor. Glioblastoma. Brisbane, Australia: Codon Publications; 2017. https:\/\/doi.org\/10.15586\/codon.glioblastoma.2017.ind."},{"key":"3386_CR19","doi-asserted-by":"publisher","unstructured":"Grochans S. et al., Epidemiology of Glioblastoma Multiforme\u2013Literature Review, May 01, 2022, MDPI. https:\/\/doi.org\/10.3390\/cancers14102412.","DOI":"10.3390\/cancers14102412"},{"issue":"1","key":"3386_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22034\/APJCP.2017.18.1.3","volume":"18","author":"F Hanif","year":"2017","unstructured":"Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3\u20139. https:\/\/doi.org\/10.22034\/APJCP.2017.18.1.3.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"27","key":"3386_CR21","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.2174\/0929867324666170516123206","volume":"24","author":"R Batash","year":"2017","unstructured":"Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem. 2017;24(27):3002\u20139. https:\/\/doi.org\/10.2174\/0929867324666170516123206.","journal-title":"Curr Med Chem"},{"key":"3386_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.03.057","author":"C Raza","year":"2019","unstructured":"Raza C, Anjum R, Shakeel NulA. Parkinson\u2019s disease: mechanisms, translational models and management strategies. Life Sci. 2019. https:\/\/doi.org\/10.1016\/j.lfs.2019.03.057.","journal-title":"Life Sci"},{"key":"3386_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22360","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2019.22360.","journal-title":"JAMA"},{"key":"3386_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES25245789","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R. Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules. 2020. https:\/\/doi.org\/10.3390\/MOLECULES25245789.","journal-title":"Molecules"},{"key":"3386_CR25","doi-asserted-by":"publisher","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Blackwell Publishing Ltd. 2018; https:\/\/doi.org\/10.1111\/ene.13439.","DOI":"10.1111\/ene.13439"},{"issue":"6","key":"3386_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11920-010-0150-6","volume":"12","author":"FW Lohoff","year":"2010","unstructured":"Lohoff FW. Overview of the genetics of major depressive disorder. Curr Psychiatry Rep. 2010;12(6):539\u201346. https:\/\/doi.org\/10.1007\/s11920-010-0150-6.","journal-title":"Curr Psychiatry Rep"},{"key":"3386_CR27","doi-asserted-by":"publisher","unstructured":"Otte C et al. Major depressive disorder. Nature Publishing Group. 2016. https:\/\/doi.org\/10.1038\/nrdp.2016.65.","DOI":"10.1038\/nrdp.2016.65"},{"issue":"1","key":"3386_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12987-020-00230-3","volume":"17","author":"H Kadry","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L. A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1):1\u201324. https:\/\/doi.org\/10.1186\/s12987-020-00230-3.","journal-title":"Fluids Barriers CNS"},{"key":"3386_CR29","doi-asserted-by":"publisher","unstructured":"Banks WA, Daneman R, Prat A. The Blood Brain Barrier, in Neuroimmune Pharmacology, Boston, MA: Springer US, 2008, pp. 21\u201338. https:\/\/doi.org\/10.1007\/978-0-387-72573-4_4.","DOI":"10.1007\/978-0-387-72573-4_4"},{"issue":"1","key":"3386_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3386_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20190062","volume":"217","author":"CP Profaci","year":"2020","unstructured":"Profaci CP, Munji RN, Pulido RS, Daneman R. The blood\u2013brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217(4):1\u201316. https:\/\/doi.org\/10.1084\/jem.20190062.","journal-title":"J Exp Med"},{"issue":"2","key":"3386_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s13346-019-00679-2","volume":"10","author":"L Jena","year":"2020","unstructured":"Jena L, McErlean E, McCarthy H. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme. Drug Deliv Transl Res. 2020;10(2):304\u201318. https:\/\/doi.org\/10.1007\/s13346-019-00679-2.","journal-title":"Drug Deliv Transl Res"},{"issue":"11","key":"3386_CR33","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s40263-020-00766-w","volume":"34","author":"R Haumann","year":"2020","unstructured":"Haumann R, Videira JC, Kaspers GJL, van Vuurden DG, Hulleman E. Overview of current drug delivery methods across the blood\u2013brain barrier for the treatment of primary brain tumors. CNS Drugs. 2020;34(11):1121\u201331. https:\/\/doi.org\/10.1007\/s40263-020-00766-w.","journal-title":"CNS Drugs"},{"key":"3386_CR34","unstructured":"Bhowmik D, Singh A, Gautam D, Kumar KPS. Immediate Release Drug Delivery System-A novel Drug Delivery System. J Pharm Biol Sci. 2016;4(6):197\u2013202, [Online]. Available: http:\/\/www.jpabs.org\/. Accessed 16 May 2025."},{"issue":"3","key":"3386_CR35","doi-asserted-by":"publisher","first-page":"01","DOI":"10.18231\/j.joapr.2022.10.3.1.4","volume":"10","author":"Y Bundela","year":"2022","unstructured":"Bundela Y, Agrawal D, Bhaduka G. An overview on fundamentals of immediate release drug delivery system. J Appl Pharm Res. 2022;10(3):01\u20134. https:\/\/doi.org\/10.18231\/j.joapr.2022.10.3.1.4.","journal-title":"J Appl Pharm Res"},{"issue":"3","key":"3386_CR36","first-page":"11","volume":"2","author":"MP Ratnaparkhi","year":"2013","unstructured":"Ratnaparkhi MP, Gupta JP. Sustained release oral drug delivery system-an overview. Int J Pharma Res Rev. 2013;2(3):11\u201321.","journal-title":"Int J Pharma Res Rev"},{"key":"3386_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2020.1788541","author":"S Wang","year":"2020","unstructured":"Wang S, Liu R, Fu Y, Kao WJ. Release mechanisms and applications of drug delivery systems for extended-release. Expert Opin Drug Deliv. 2020. https:\/\/doi.org\/10.1080\/17425247.2020.1788541.","journal-title":"Expert Opin Drug Deliv"},{"key":"3386_CR38","doi-asserted-by":"publisher","unstructured":"Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005;2(2):165\u201375. https:\/\/doi.org\/10.2174\/1567201053586047.","DOI":"10.2174\/1567201053586047"},{"issue":"4","key":"3386_CR39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/S13346-020-00891-5","volume":"12","author":"LA Keller","year":"2021","unstructured":"Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Delivery and Translational Research 2021 12:4. 2021;12(4):735\u201357. https:\/\/doi.org\/10.1007\/S13346-020-00891-5.","journal-title":"Drug Delivery and Translational Research 2021 12:4"},{"key":"3386_CR40","doi-asserted-by":"publisher","unstructured":"Wen J, Huang Y, Crowe TP, Hsu WH. Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System. Pharmaceutics. 2022;14(629):14. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14030629.","DOI":"10.3390\/PHARMACEUTICS14030629"},{"key":"3386_CR41","unstructured":"Gaikwad AK. Transdermal drug delivery system: Formulation aspects and evaluation. Comprehens J Pharm Sci. 2013;1(1):1\u201310. [Online]. Available: http:\/\/www.knowledgebasepublishers.org\/maincjps.html. Accessed 16 May 2025."},{"key":"3386_CR42","doi-asserted-by":"publisher","unstructured":"Rastogi V, Yadav P. Transdermal drug delivery system: An overview. Asian J Pharm (AJP). 2012;6(3). https:\/\/doi.org\/10.22377\/AJP.V6I3.51.","DOI":"10.22377\/AJP.V6I3.51"},{"issue":"1","key":"3386_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40824-021-00226-6\/FIGURES\/6","volume":"25","author":"WY Jeong","year":"2021","unstructured":"Jeong WY, Kwon M, Choi HE, Kim KS. Recent advances in transdermal drug delivery systems: a review. Biomater Res. 2021;25(1):1\u201315. https:\/\/doi.org\/10.1186\/S40824-021-00226-6\/FIGURES\/6.","journal-title":"Biomater Res"},{"issue":"4","key":"3386_CR44","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1227\/01.neu.0000175731.25414.4c","volume":"57","author":"LL Muldoon","year":"2005","unstructured":"Muldoon LL, S\u00e0ndor M, Pinkston KE, Neuwelt EA. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery. 2005;57(4):785\u201396. https:\/\/doi.org\/10.1227\/01.neu.0000175731.25414.4c.","journal-title":"Neurosurgery"},{"key":"3386_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/WNAN.1479","author":"RW Chakroun","year":"2018","unstructured":"Chakroun RW, Zhang P, Lin R, Schiapparelli P, Quinones-Hinojosa A, Cui H. Nanotherapeutic systems for local treatment of brain tumors. WIREs Nanomed Nanobiotechnol. 2018. https:\/\/doi.org\/10.1002\/WNAN.1479.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"3386_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030774","author":"Y Jia","year":"2023","unstructured":"Jia Y, et al. Approved nanomedicine against diseases. MDPI. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15030774.","journal-title":"MDPI"},{"issue":"10","key":"3386_CR47","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/S11095-016-1958-5\/TABLES\/1","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373\u201387. https:\/\/doi.org\/10.1007\/S11095-016-1958-5\/TABLES\/1.","journal-title":"Pharm Res"},{"issue":"5","key":"3386_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood\u2013brain barrier. Nature Reviews Drug Discovery 2021 20:5. 2021;20(5):362\u201383. https:\/\/doi.org\/10.1038\/s41573-021-00139-y.","journal-title":"Nature Reviews Drug Discovery 2021 20:5"},{"key":"3386_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/PH16081056","author":"R Raju","year":"2023","unstructured":"Raju R, Abuwatfa WH, Pitt WG, Husseini GA. Liposomes for the treatment of brain cancer\u2014a review. Pharmaceuticals. 2023. https:\/\/doi.org\/10.3390\/PH16081056.","journal-title":"Pharmaceuticals"},{"key":"3386_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2015.00286\/BIBTEX","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:163819. https:\/\/doi.org\/10.3389\/FPHAR.2015.00286\/BIBTEX.","journal-title":"Front Pharmacol"},{"key":"3386_CR51","doi-asserted-by":"publisher","unstructured":"Bahram M, Mohseni N, Moghtader M. An Introduction to Hydrogels and Some Recent Applications, in Emerging Concepts in Analysis and Applications of Hydrogels. InTech, 2016, pp. 10\u201338. https:\/\/doi.org\/10.5772\/64301.","DOI":"10.5772\/64301"},{"key":"3386_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/FCHEM.2024.1336717\/BIBTEX","volume":"12","author":"A Raeisi","year":"2024","unstructured":"Raeisi A, Farjadian F. Commercial hydrogel product for drug delivery based on route of administration. Front Chem. 2024;12:1336717. https:\/\/doi.org\/10.3389\/FCHEM.2024.1336717\/BIBTEX.","journal-title":"Front Chem"},{"key":"3386_CR53","doi-asserted-by":"publisher","DOI":"10.1088\/1748-6041\/7\/2\/024101","author":"MM Pakulska","year":"2012","unstructured":"Pakulska MM, Ballios BG, Shoichet MS. Injectable hydrogels for central nervous system therapy. Biomed Mater. 2012. https:\/\/doi.org\/10.1088\/1748-6041\/7\/2\/024101.","journal-title":"Biomed Mater"},{"issue":"1","key":"3386_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-018-0491-8","volume":"25","author":"R Boni","year":"2018","unstructured":"Boni R, Ali A, Shavandi A, Clarkson AN. Current and novel polymeric biomaterials for neural tissue engineering. J Biomed Sci. 2018;25(1):1\u201321. https:\/\/doi.org\/10.1186\/s12929-018-0491-8.","journal-title":"J Biomed Sci"},{"issue":"13","key":"3386_CR55","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1016\/j.biomaterials.2012.01.044","volume":"33","author":"PM Crapo","year":"2012","unstructured":"Crapo PM, et al. Biologic scaffolds composed of central nervous system extracellular matrix. Biomaterials. 2012;33(13):3539\u201347. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.01.044.","journal-title":"Biomaterials"},{"key":"3386_CR56","doi-asserted-by":"publisher","unstructured":"Calori IR, Braga G, de Jesus PD, Bi H, Tedesco AC, Polymer scaffolds as drug delivery systems, Apr. 15, 2020, Elsevier Ltd. https:\/\/doi.org\/10.1016\/j.eurpolymj.2020.109621.","DOI":"10.1016\/j.eurpolymj.2020.109621"},{"issue":"6","key":"3386_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2165\/00003088-200241060-00002","volume":"41","author":"AB Fleming","year":"2002","unstructured":"Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403\u201319. https:\/\/doi.org\/10.2165\/00003088-200241060-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3386_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/aian.AIAN_241_17","volume":"20","author":"S Ovallath","year":"2017","unstructured":"Ovallath S, Sulthana B. Levodopa: history and therapeutic applications. Ann Indian Acad Neurol. 2017;20(3):185\u20139. https:\/\/doi.org\/10.4103\/aian.AIAN_241_17.","journal-title":"Ann Indian Acad Neurol"},{"key":"3386_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5741-y","author":"O Hornykiewicz","year":"2010","unstructured":"Hornykiewicz O. A brief history of levodopa. J Neurol. 2010. https:\/\/doi.org\/10.1007\/s00415-010-5741-y.","journal-title":"J Neurol"},{"key":"3386_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00769-7","author":"D Urso","year":"2020","unstructured":"Urso D, Chaudhuri KR, Qamar MA, Jenner P, Adis. Improving the delivery of Levodopa in Parkinson\u2019s disease: a review of approved and emerging therapies. CNS Drugs. 2020. https:\/\/doi.org\/10.1007\/s40263-020-00769-7.","journal-title":"CNS Drugs"},{"key":"3386_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27216","author":"CW Olanow","year":"2018","unstructured":"Olanow CW, Stocchi F, John Wiley and Sons Inc. Levodopa: a new look at an old friend. Mov Disord. 2018. https:\/\/doi.org\/10.1002\/mds.27216.","journal-title":"Mov Disord"},{"issue":"5","key":"3386_CR62","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1021\/OP1000989","volume":"14","author":"M \u017divec","year":"2010","unstructured":"\u017divec M, An\u017ei\u010d B, Gobec S. A novel scalable synthesis of pramipexole. Org Process Res Dev. 2010;14(5):1125\u20139. https:\/\/doi.org\/10.1021\/OP1000989.","journal-title":"Org Process Res Dev"},{"issue":"10","key":"3386_CR63","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","volume":"24","author":"A Antonini","year":"2010","unstructured":"Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G. Role of pramipexole in the management of Parkinson\u02bcs disease. CNS Drugs. 2010;24(10):829\u201341. https:\/\/doi.org\/10.2165\/11585090-000000000-00000.","journal-title":"CNS Drugs"},{"key":"3386_CR64","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/ene.13303","volume":"24","author":"T Shen","year":"2017","unstructured":"Shen T, Ye R, Zhang B. Efficacy and safety of pramipexole extended-release in Parkinson\u2019s disease: a review based on meta-analysis of randomized controlled trials. Eur J Neurol. 2017;24:835\u201343. https:\/\/doi.org\/10.1111\/ene.13303.","journal-title":"Eur J Neurol"},{"issue":"18","key":"3386_CR65","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s40265-014-0322-5","volume":"74","author":"JE Frampton","year":"2014","unstructured":"Frampton JE. Pramipexole extended-release: a review of its use in patients with Parkinson\u2019s disease. Drugs. 2014;74(18):2175\u201390. https:\/\/doi.org\/10.1007\/s40265-014-0322-5.","journal-title":"Drugs"},{"issue":"1","key":"3386_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0022-510X(98)00307-4","volume":"163","author":"JP Bennett","year":"1999","unstructured":"Bennett JP, Piercey MF. Pramipexole \u2014 a new dopamine agonist for the treatment of Parkinson\u2019s disease. J Neurol Sci. 1999;163(1):25\u201331. https:\/\/doi.org\/10.1016\/S0022-510X(98)00307-4.","journal-title":"J Neurol Sci"},{"key":"3386_CR67","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejpb.2018.02.031","volume":"127","author":"DR Kalaria","year":"2018","unstructured":"Kalaria DR, Singhal M, Patravale V, Merino V, Kalia YN. Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: transdermal polypharmacy to treat Parkinson\u2019s disease. Eur J Pharm Biopharm. 2018;127:204\u201312. https:\/\/doi.org\/10.1016\/j.ejpb.2018.02.031.","journal-title":"Eur J Pharm Biopharm"},{"key":"3386_CR68","doi-asserted-by":"publisher","unstructured":"D. JS, S. BC, M. M. Duloxetine, The Essence of Analgesia and Analgesics, 2019, pp. 353\u2013356. https:\/\/doi.org\/10.1017\/CBO9780511841378.087.","DOI":"10.1017\/CBO9780511841378.087"},{"key":"3386_CR69","doi-asserted-by":"publisher","unstructured":"Muscatello MRA et al. Duloxetine in psychiatric disorders: Expansions beyond major depression and generalized anxiety disorder, Front. Psychiatry. 2019;10(OCT):449672. https:\/\/doi.org\/10.3389\/FPSYT.2019.00772\/BIBTEX.","DOI":"10.3389\/FPSYT.2019.00772\/BIBTEX"},{"issue":"1","key":"3386_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/S40266-012-0040-1\/TABLES\/7","volume":"30","author":"S Dhillon","year":"2013","unstructured":"Dhillon S. Duloxetine: a review of its use in the management of major depressive disorder in older adults. Drugs Aging. 2013;30(1):59\u201379. https:\/\/doi.org\/10.1007\/S40266-012-0040-1\/TABLES\/7.","journal-title":"Drugs Aging"},{"key":"3386_CR71","unstructured":"Onu\u0163u AH. Duloxetine, an antidepressant with analgesic properties \u2013 a preliminary analysis. Rom. J. Anaesth. Intensive Care. 2015;22(2):123. [Online]. Available: \/pmc\/articles\/PMC5505372\/. Accessed 14 Jan 2024."},{"key":"3386_CR72","doi-asserted-by":"publisher","unstructured":"Ch S et al. Formulation development and evaluation of duloxetine extended-release tablets, World Journal of Current Medical and Pharmaceutical Research. 2021; pp. 62\u201367. https:\/\/doi.org\/10.37022\/WJCMPR.VI.178.","DOI":"10.37022\/WJCMPR.VI.178"},{"issue":"1","key":"3386_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40543-016-0105-6\/TABLES\/6","volume":"7","author":"A Singh","year":"2016","unstructured":"Singh A, Bali A. Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride. J Anal Sci Technol. 2016;7(1):1\u201313. https:\/\/doi.org\/10.1186\/S40543-016-0105-6\/TABLES\/6.","journal-title":"J Anal Sci Technol"},{"key":"3386_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-008055232-3.61216-4","volume-title":"xPharm: the comprehensive pharmacology reference","author":"W Marsh","year":"2007","unstructured":"Marsh W. Amitriptyline. In: xPharm: the comprehensive pharmacology reference. Elsevier; 2007. p. 1\u20136. https:\/\/doi.org\/10.1016\/B978-008055232-3.61216-4."},{"issue":"1","key":"3386_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13643-020-01296-8\/TABLES\/4","volume":"9","author":"MS Brueckle","year":"2020","unstructured":"Brueckle MS, et al. Adverse drug reactions associated with amitriptyline - Protocol for a systematic multiple-indication review and meta-analysis. Syst Rev. 2020;9(1):1\u20138. https:\/\/doi.org\/10.1186\/S13643-020-01296-8\/TABLES\/4.","journal-title":"Syst Rev"},{"key":"3386_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-56015-1_81-1","volume-title":"NeuroPsychopharmacotherapy","author":"MP Davis","year":"2020","unstructured":"Davis MP. Amitriptyline and depressions. In: NeuroPsychopharmacotherapy. Springer International Publishing; 2020. p. 1\u201319. https:\/\/doi.org\/10.1007\/978-3-319-56015-1_81-1."},{"issue":"3","key":"3386_CR77","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1021\/ACSCHEMNEURO.0C00467\/ASSET\/IMAGES\/LARGE\/CN0C00467_0002.JPEG","volume":"12","author":"EW McClure","year":"2021","unstructured":"McClure EW, Daniels RN. Classics in chemical neuroscience: amitriptyline. ACS Chem Neurosci. 2021;12(3):354\u201362. https:\/\/doi.org\/10.1021\/ACSCHEMNEURO.0C00467\/ASSET\/IMAGES\/LARGE\/CN0C00467_0002.JPEG.","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"3386_CR78","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1124\/JPET.118.255828","volume":"370","author":"G Kaur","year":"2019","unstructured":"Kaur G, Arora M, Kumar MNVR. Oral drug delivery technologies\u2014a decade of developments. J Pharmacol Exp Ther. 2019;370(3):529\u201343. https:\/\/doi.org\/10.1124\/JPET.118.255828.","journal-title":"J Pharmacol Exp Ther"},{"key":"3386_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.05.015","author":"AO Tijani","year":"2021","unstructured":"Tijani AO, Nunez E, Singh K, Khanna G, Puri A. Transdermal route: a viable option for systemic delivery of antidepressants. J Pharm Sci. 2021. https:\/\/doi.org\/10.1016\/j.xphs.2021.05.015.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"3386_CR80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/J.IJPHARM.2016.11.038","volume":"517","author":"S del R\u00edo-Sancho","year":"2017","unstructured":"del R\u00edo-Sancho S, et al. Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport. Int J Pharm. 2017;517(1\u20132):104\u201311. https:\/\/doi.org\/10.1016\/J.IJPHARM.2016.11.038.","journal-title":"Int J Pharm"},{"issue":"10","key":"3386_CR81","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/14740338.2018.1524870","volume":"17","author":"S Matsunaga","year":"2018","unstructured":"Matsunaga S, et al. The efficacy and safety of memantine for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Saf. 2018;17(10):1053\u201361. https:\/\/doi.org\/10.1080\/14740338.2018.1524870.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"3386_CR82","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/IBRA.12098","volume":"9","author":"BC Tang","year":"2023","unstructured":"Tang BC, Wang YT, Ren J. Basic information about memantine and its treatment of Alzheimer\u2019s disease and other clinical applications. Ibrain. 2023;9(3):340\u20138. https:\/\/doi.org\/10.1002\/IBRA.12098.","journal-title":"Ibrain"},{"key":"3386_CR83","doi-asserted-by":"publisher","unstructured":"McShane R et al. Memantine for dementia. John Wiley and Sons Ltd. 2019; https:\/\/doi.org\/10.1002\/14651858.CD003154.pub6.","DOI":"10.1002\/14651858.CD003154.pub6"},{"key":"3386_CR84","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170424","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer\u2019s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2017. https:\/\/doi.org\/10.3233\/JAD-170424.","journal-title":"J Alzheimers Dis"},{"key":"3386_CR85","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.JCONREL.2019.03.022","volume":"303","author":"R Kanasty","year":"2019","unstructured":"Kanasty R, et al. A pharmaceutical answer to nonadherence: once weekly oral memantine for Alzheimer\u2019s disease. J Control Release. 2019;303:34\u201341. https:\/\/doi.org\/10.1016\/J.JCONREL.2019.03.022.","journal-title":"J Control Release"},{"key":"3386_CR86","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.493874","author":"N Bassil","year":"2010","unstructured":"Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer\u2019s disease. Expert Opin Pharmacother. 2010. https:\/\/doi.org\/10.1517\/14656566.2010.493874.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"3386_CR87","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3233\/JAD-210524","volume":"82","author":"K Sato","year":"2021","unstructured":"Sato K, Mano T, Iwata A, Toda T. Safety of memantine in combination with potentially interactive drugs in the real world: a pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database. J Alzheimers Dis. 2021;82(3):1333\u201344. https:\/\/doi.org\/10.3233\/JAD-210524.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"3386_CR88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/S11060-020-03598-2\/FIGURES\/1","volume":"151","author":"KM Hotchkiss","year":"2021","unstructured":"Hotchkiss KM, Sampson JH. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. J Neurooncol. 2021;151(1):55\u201362. https:\/\/doi.org\/10.1007\/S11060-020-03598-2\/FIGURES\/1.","journal-title":"J Neurooncol"},{"issue":"1","key":"3386_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5306\/WJCO.V5.I1.19","volume":"5","author":"W Zhu","year":"2014","unstructured":"Zhu W, Zhou L, Qian JQ, Qiu TZ, Shu YQ, Liu P. Temozolomide for treatment of brain metastases: a review of 21 clinical trials. World J Clin Oncol. 2014;5(1):19. https:\/\/doi.org\/10.5306\/WJCO.V5.I1.19.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"3386_CR90","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/CDR.2020.79","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resistance. 2021;4(1):17. https:\/\/doi.org\/10.20517\/CDR.2020.79.","journal-title":"Cancer Drug Resistance"},{"issue":"13","key":"3386_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14133203","volume":"14","author":"JVR Cruz","year":"2022","unstructured":"Cruz JVR, et al. Obstacles to glioblastoma treatment two decades after temozolomide. Cancers. 2022;14(13):3203. https:\/\/doi.org\/10.3390\/CANCERS14133203.","journal-title":"Cancers"},{"key":"3386_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2023.115174","volume":"165","author":"A Krajcer","year":"2023","unstructured":"Krajcer A, Grzywna E, Lewandowska-\u0141a\u0144cucka J. Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy. Biomed Pharmacother. 2023;165:115174. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.115174.","journal-title":"Biomed Pharmacother"},{"key":"3386_CR93","doi-asserted-by":"publisher","unstructured":"Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer\u2019s disease. John Wiley and Sons Ltd. 2018; https:\/\/doi.org\/10.1002\/14651858.CD001190.pub3.","DOI":"10.1002\/14651858.CD001190.pub3"},{"issue":"1","key":"3386_CR94","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1021\/ACSCHEMNEURO.8B00517\/ASSET\/IMAGES\/LARGE\/CN-2018-005176_0007.JPEG","volume":"10","author":"JT Brewster","year":"2019","unstructured":"Brewster JT, Dell\u2019Acqua S, Thach DQ, Sessler JL. Classics in chemical neuroscience: donepezil. ACS Chem Neurosci. 2019;10(1):155\u201367. https:\/\/doi.org\/10.1021\/ACSCHEMNEURO.8B00517\/ASSET\/IMAGES\/LARGE\/CN-2018-005176_0007.JPEG.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"3386_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS11020064","volume":"11","author":"LC Espinoza","year":"2019","unstructured":"Espinoza LC, et al. Formulation strategies to improve nose-to-brain delivery of donepezil. Pharmaceutics. 2019;11(2):64. https:\/\/doi.org\/10.3390\/PHARMACEUTICS11020064.","journal-title":"Pharmaceutics"},{"key":"3386_CR96","doi-asserted-by":"publisher","unstructured":"Zeb MW, Riaz A, Szigeti K. Donepezil: A review of pharmacological characteristics and role in the management of Alzheimer disease. Libertas Academica Ltd. 2017; https:\/\/doi.org\/10.1177\/1179553017695258.","DOI":"10.1177\/1179553017695258"},{"key":"3386_CR97","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00290","author":"ZQ Zhao","year":"2021","unstructured":"Zhao ZQ, Chen BZ, Zhang XP, Zheng H, Guo XD. An update on the routes for the delivery of donepezil. Mol Pharm. 2021. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00290.","journal-title":"Mol Pharm"},{"key":"3386_CR98","doi-asserted-by":"publisher","unstructured":"Wang E. The Controversy Over the Use of Prozac Because of Side Effects,\u201d Proceedings of the 2021 International Conference on Public Art and Human Development ( ICPAHD 2021). 2022;638:128\u2013132. https:\/\/doi.org\/10.2991\/ASSEHR.K.220110.025.","DOI":"10.2991\/ASSEHR.K.220110.025"},{"issue":"12","key":"3386_CR99","doi-asserted-by":"publisher","first-page":"333","DOI":"10.6919\/ICJE.202012_6(12).0049","volume":"6","author":"H Li","year":"2020","unstructured":"Li H. An overview of depression and two antidepressants-selegiline and fluoxetine. Int Core J Eng. 2020;6(12):333\u201348. https:\/\/doi.org\/10.6919\/ICJE.202012_6(12).0049.","journal-title":"Int Core J Eng"},{"key":"3386_CR100","doi-asserted-by":"publisher","unstructured":"Perez-Caballero L, Torres-Sanchez S, Bravo L, Mico JA, Berrocoso E. Fluoxetine: A case history of its discovery and preclinical development, Informa Healthcare. 2014. https:\/\/doi.org\/10.1517\/17460441.2014.907790.","DOI":"10.1517\/17460441.2014.907790"},{"issue":"1\u20132","key":"3386_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijpharm.2015.04.012","volume":"487","author":"E Jung","year":"2015","unstructured":"Jung E, et al. Development of drug-in-adhesive patch formulations for transdermal delivery of fluoxetine: in vitro and in vivo evaluations. Int J Pharm. 2015;487(1\u20132):49\u201355. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.04.012.","journal-title":"Int J Pharm"},{"issue":"1","key":"3386_CR102","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/nmt-2020-0052","volume":"11","author":"K Nguyen","year":"2021","unstructured":"Nguyen K, Hoffman H, Chakkamparambil B, Grossberg GT. Evaluation of rivastigmine in Alzheimer\u2019s disease. Neurodegener Dis Manag. 2021;11(1):35\u201348. https:\/\/doi.org\/10.2217\/nmt-2020-0052.","journal-title":"Neurodegener Dis Manag"},{"key":"3386_CR103","doi-asserted-by":"publisher","unstructured":"Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer\u2019s disease, John Wiley and Sons Ltd. 2015; https:\/\/doi.org\/10.1002\/14651858.CD001191.pub4.","DOI":"10.1002\/14651858.CD001191.pub4"},{"issue":"2","key":"3386_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.16142","volume":"31","author":"S Reilly","year":"2024","unstructured":"Reilly S, Dhaliwal S, Arshad U, Macerollo A, Husain N, Da Costa A. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson\u2019s disease: a systematic review. Eur J Neurol. 2024;31(2):e16142. https:\/\/doi.org\/10.1111\/ENE.16142.","journal-title":"Eur J Neurol"},{"issue":"5","key":"3386_CR105","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/J.1742-1241.2009.02052.X","volume":"63","author":"A Kurz","year":"2009","unstructured":"Kurz A, Farlow M, Lef\u00e8vre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer\u2019s disease: a review. Int J Clin Pract. 2009;63(5):799\u2013805. https:\/\/doi.org\/10.1111\/J.1742-1241.2009.02052.X.","journal-title":"Int J Clin Pract"},{"key":"3386_CR106","doi-asserted-by":"publisher","DOI":"10.1177\/2042098617750555","author":"R Khoury","year":"2018","unstructured":"Khoury R, Rajamanickam J, Grossberg GT, SAGE Publications Ltd. An update on the safety of current therapies for Alzheimer\u2019s disease: focus on rivastigmine. Ther Adv Drug Saf. 2018. https:\/\/doi.org\/10.1177\/2042098617750555.","journal-title":"Ther Adv Drug Saf"},{"key":"3386_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2023.114824","volume":"197","author":"PR Brewster","year":"2023","unstructured":"Brewster PR, Bari SMI, Walker GM, Werfel TA. Current and future directions of drug delivery for the treatment of mental illnesses. Adv Drug Deliv Rev. 2023;197:114824. https:\/\/doi.org\/10.1016\/J.ADDR.2023.114824.","journal-title":"Adv Drug Deliv Rev"},{"key":"3386_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.01036","author":"ZZ Xiao","year":"2020","unstructured":"Xiao ZZ, et al. Carmustine as a supplementary therapeutic option for glioblastoma: a systematic review and meta-analysis. Front Neurol. 2020. https:\/\/doi.org\/10.3389\/fneur.2020.01036.","journal-title":"Front Neurol"},{"issue":"3","key":"3386_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES9030324","volume":"9","author":"JP Fisher","year":"2021","unstructured":"Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9(3):324. https:\/\/doi.org\/10.3390\/BIOMEDICINES9030324.","journal-title":"Biomedicines"},{"key":"3386_CR110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","volume":"54","author":"T Tykocki","year":"2018","unstructured":"Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7\u201313. https:\/\/doi.org\/10.1016\/j.jocn.2018.05.002.","journal-title":"J Clin Neurosci"},{"issue":"10","key":"3386_CR111","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/JOP.2017.025536","volume":"13","author":"JY Nam","year":"2017","unstructured":"Nam JY, De Groot JF. Treatment of glioblastoma. J Oncol Pract. 2017;13(10):629\u201338. https:\/\/doi.org\/10.1200\/JOP.2017.025536.","journal-title":"J Oncol Pract"},{"issue":"1","key":"3386_CR112","doi-asserted-by":"publisher","first-page":"84","DOI":"10.54565\/JPHCFUM.1090661","volume":"5","author":"LO Ahmed","year":"2022","unstructured":"Ahmed LO, Omer RA, Qader IN, Koparir P. Theoretical analysis of the reactivity of carmustine and lomustine drugs. Journal of Physical Chemistry and Functional Materials. 2022;5(1):84\u201396. https:\/\/doi.org\/10.54565\/JPHCFUM.1090661.","journal-title":"Journal of Physical Chemistry and Functional Materials"},{"key":"3386_CR113","unstructured":"DrugBank, Carmustine: Uses, Interactions, Mechanism of Action | DrugBank Online. [Online]. Available: https:\/\/go.drugbank.com\/drugs\/DB00262. Accessed 15 Mar 2025."},{"issue":"4","key":"3386_CR114","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s0305-7372(82)80043-1","volume":"9","author":"RB Weiss","year":"1982","unstructured":"Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev. 1982;9(4):313\u201330. https:\/\/doi.org\/10.1016\/s0305-7372(82)80043-1.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3386_CR115","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/IJC.22305","volume":"120","author":"B Jacques-Olivier","year":"2007","unstructured":"Jacques-Olivier B, et al. Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study. Int J Cancer. 2007;120(8):1782\u20136. https:\/\/doi.org\/10.1002\/IJC.22305.","journal-title":"Int J Cancer"},{"issue":"1","key":"3386_CR116","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/S11060-019-03266-0\/TABLES\/4","volume":"145","author":"P Yerram","year":"2019","unstructured":"Yerram P, Reiss SN, Modelevsky L, Gavrilovic IT, Kaley T. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. J Neurooncol. 2019;145(1):57\u201363. https:\/\/doi.org\/10.1007\/S11060-019-03266-0\/TABLES\/4.","journal-title":"J Neurooncol"},{"key":"3386_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780. https:\/\/doi.org\/10.1016\/j.phrs.2021.105780.","journal-title":"Pharmacol Res"},{"key":"3386_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120479","author":"N Fattahi","year":"2021","unstructured":"Fattahi N, Ramazani A, Hamidi M, Parsa M, Rostamizadeh K, Rashidzadeh H. Enhancement of the brain delivery of methotrexate with administration of mid-chain ester prodrugs: in vitro and in vivo studies. Int J Pharm. 2021. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120479.","journal-title":"Int J Pharm"},{"issue":"6","key":"3386_CR119","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/jcbfm.2015.6","volume":"35","author":"I Cooper","year":"2015","unstructured":"Cooper I, et al. Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors. J Cereb Blood Flow Metab. 2015;35(6):967\u201376. https:\/\/doi.org\/10.1038\/jcbfm.2015.6.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"3386_CR120","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1007\/S11033-020-05481-9\/FIGURES\/3","volume":"47","author":"V Maksimovic","year":"2020","unstructured":"Maksimovic V, et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020;47(6):4699\u2013708. https:\/\/doi.org\/10.1007\/S11033-020-05481-9\/FIGURES\/3.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"3386_CR121","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/S00280-012-2062-0","volume":"71","author":"SS Abolmaali","year":"2013","unstructured":"Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol. 2013;71(5):1115\u201330. https:\/\/doi.org\/10.1007\/S00280-012-2062-0.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3386_CR122","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/eje.1.02312","volume":"156","author":"I Schreiber","year":"2007","unstructured":"Schreiber I, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156(1):75\u201382. https:\/\/doi.org\/10.1530\/eje.1.02312.","journal-title":"Eur J Endocrinol"},{"issue":"24","key":"3386_CR123","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMRA062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S. Acromegaly. N Engl J Med. 2006;355(24):2558\u201373. https:\/\/doi.org\/10.1056\/NEJMRA062453.","journal-title":"N Engl J Med"},{"key":"3386_CR124","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.148s021","author":"JJ Kopchick","year":"2003","unstructured":"Kopchick JJ. Discovery and mechanism of action of pegvisomant. Eur J Endocrinol. 2003. https:\/\/doi.org\/10.1530\/eje.0.148s021.","journal-title":"Eur J Endocrinol"},{"issue":"36","key":"3386_CR125","doi-asserted-by":"publisher","first-page":"21969","DOI":"10.1074\/JBC.271.36.21969","volume":"271","author":"R Clark","year":"1996","unstructured":"Clark R, et al. Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol. J Biol Chem. 1996;271(36):21969\u201377. https:\/\/doi.org\/10.1074\/JBC.271.36.21969.","journal-title":"J Biol Chem"},{"issue":"11","key":"3386_CR126","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1210\/CLINEM\/DGAB529","volume":"106","author":"PS Thornton","year":"2021","unstructured":"Thornton PS, et al. Weekly Lonapegsomatropin in Treatment-Na\u00efve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. J Clin Endocrinol Metab. 2021;106(11):3184\u201395. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB529.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3386_CR127","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/S13346-019-00631-4","volume":"9","author":"Z Hussain","year":"2019","unstructured":"Hussain Z, Khan S, Imran M, Sohail M, Shah SWA, de Matas M. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution. Drug Deliv Transl Res. 2019;9(3):721\u201334. https:\/\/doi.org\/10.1007\/S13346-019-00631-4.","journal-title":"Drug Deliv Transl Res"},{"key":"3386_CR128","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2014.866651","author":"D Vllasaliu","year":"2014","unstructured":"Vllasaliu D, Fowler R, Stolnik S. PEGylated nanomedicines: recent progress and remaining concerns. Expert Opin Drug Deliv. 2014. https:\/\/doi.org\/10.1517\/17425247.2014.866651.","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"3386_CR129","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/02656730903287790","volume":"25","author":"A Jordan","year":"2009","unstructured":"Jordan A, Wust P, F\u00e4hling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia. 2009;25(7):499\u2013511. https:\/\/doi.org\/10.3109\/02656730903287790.","journal-title":"Int J Hyperthermia"},{"issue":"1","key":"3386_CR130","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/S11060-006-9195-0\/METRICS","volume":"81","author":"K Maier-Hauff","year":"2007","unstructured":"Maier-Hauff K, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81(1):53\u201360. https:\/\/doi.org\/10.1007\/S11060-006-9195-0\/METRICS.","journal-title":"J Neurooncol"},{"issue":"2","key":"3386_CR131","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/S11060-010-0389-0\/FIGURES\/2","volume":"103","author":"K Maier-Hauff","year":"2011","unstructured":"Maier-Hauff K, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317\u201324. https:\/\/doi.org\/10.1007\/S11060-010-0389-0\/FIGURES\/2.","journal-title":"J Neurooncol"},{"issue":"6","key":"3386_CR132","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/02656730802104757","volume":"24","author":"B Thiesen","year":"2008","unstructured":"Thiesen B, Jordan A. Clinical applications of magnetic nanoparticles for hyperthermia. Int J Hyperthermia. 2008;24(6):467\u201374. https:\/\/doi.org\/10.1080\/02656730802104757.","journal-title":"Int J Hyperthermia"},{"key":"3386_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae - the first FDA-approved nano-drug: lessons learned. J Control Release. 2012. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release"},{"key":"3386_CR134","doi-asserted-by":"publisher","unstructured":"Goren D, Gabizon A, Barenholz Y. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. Biochim Biophys Acta. 1990;1029(2):285\u201394. https:\/\/doi.org\/10.1016\/0005-2736(90)90165-k.","DOI":"10.1016\/0005-2736(90)90165-k"},{"key":"3386_CR135","unstructured":"Marina NM et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study., Clin Cancer Res. 2002;8(2):413\u20138, [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11839657"},{"issue":"11","key":"3386_CR136","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jocn.2011.02.026","volume":"18","author":"S Ananda","year":"2011","unstructured":"Ananda S, et al. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci. 2011;18(11):1444\u20138. https:\/\/doi.org\/10.1016\/j.jocn.2011.02.026.","journal-title":"J Clin Neurosci"},{"issue":"3","key":"3386_CR137","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1023\/A:1015752331041\/METRICS","volume":"57","author":"KA Jaeckle","year":"2002","unstructured":"Jaeckle KA, et al. An open label trial of sustained-release cytarabine (DepoCyt\u8482) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002;57(3):231\u20139. https:\/\/doi.org\/10.1023\/A:1015752331041\/METRICS.","journal-title":"J Neurooncol"},{"issue":"6","key":"3386_CR138","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/S42399-020-00322-Z","volume":"2","author":"BM Frankel","year":"2020","unstructured":"Frankel BM, Cachia D, Patel SJ, Das A. Targeting subventricular zone progenitor cells with intraventricular liposomal encapsulated cytarabine in patients with secondary glioblastoma: a report of two cases. SN Compr Clin Med. 2020;2(6):836\u201343. https:\/\/doi.org\/10.1007\/S42399-020-00322-Z.","journal-title":"SN Compr Clin Med"},{"key":"3386_CR139","unstructured":"Kim S, Kim DJ, Geyer MA, Howell SB. Multi vesicular Liposomes Containing 1-^-D-Arabinofuranosylcytosine for Slow-Release Intrathecal Therapy1, 1987. [Online]. Available: http:\/\/aacrjournals.org\/cancerres\/article-pdf\/47\/15\/3935\/2429082\/cr0470153935.pdf"},{"key":"3386_CR140","unstructured":"Glantz MJ et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999;5(11):3394\u2013402. [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10589750"},{"key":"3386_CR141","unstructured":"Zentner GM. et al., Biodegradable block copolymers for delivery of proteins and q water-insoluble drugs, 2001. [Online]. Available: www.elsevier.com\/locate\/jconrel"},{"key":"3386_CR142","doi-asserted-by":"publisher","unstructured":"Elstad NL, Fowers KD. OncoGel (ReGel\/paclitaxel) - Clinical applications for a novel paclitaxel delivery system. 2009. https:\/\/doi.org\/10.1016\/j.addr.2009.04.010.","DOI":"10.1016\/j.addr.2009.04.010"},{"issue":"3","key":"3386_CR143","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/CAD.0b013e328011a51d","volume":"18","author":"SJ Vukelja","year":"2007","unstructured":"Vukelja SJ, et al. Phase 1 study of escalating-dose OncoGel (ReGel\/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs. 2007;18(3):283\u20139. https:\/\/doi.org\/10.1097\/CAD.0b013e328011a51d.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"3386_CR144","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3171\/2009.11.JNS08162","volume":"113","author":"B Tyler","year":"2010","unstructured":"Tyler B, et al. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats: laboratory investigation. J Neurosurg. 2010;113(2):210\u20137. https:\/\/doi.org\/10.3171\/2009.11.JNS08162.","journal-title":"J Neurosurg"},{"issue":"10","key":"3386_CR145","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1245\/S10434-008-0048-2\/FIGURES\/2","volume":"15","author":"FJ Attenello","year":"2008","unstructured":"Attenello FJ, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887\u201393. https:\/\/doi.org\/10.1245\/S10434-008-0048-2\/FIGURES\/2.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3386_CR146","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/0019-509X.76623","volume":"48","author":"M Panigrahi","year":"2011","unstructured":"Panigrahi M, Das PK, Parikh PM. Brain tumor and Gliadel wafer treatment. Indian J Cancer. 2011;48(1):11\u20137. https:\/\/doi.org\/10.4103\/0019-509X.76623.","journal-title":"Indian J Cancer"},{"issue":"7","key":"3386_CR147","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/J.APSB.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049. https:\/\/doi.org\/10.1016\/J.APSB.2022.02.002.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3386_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S41231-019-0050-7","volume":"4","author":"AA Seyhan","year":"2019","unstructured":"Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles. Transl Med Commun. 2019;4(1):1\u201319. https:\/\/doi.org\/10.1186\/S41231-019-0050-7.","journal-title":"Transl Med Commun"},{"issue":"10","key":"3386_CR149","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.3390\/PR11102919","volume":"11","author":"M Malamatari","year":"2023","unstructured":"Malamatari M. The Importance of Drug Delivery in the Clinical Development and Lifecycle of Drug Products with Examples from Authorised Medicinal Products. Processes. 2023;11(10):2919. https:\/\/doi.org\/10.3390\/PR11102919.","journal-title":"Processes"},{"key":"3386_CR150","doi-asserted-by":"publisher","unstructured":"Shahiwala A. Advancing drug delivery research: sustainable strategies for innovation and translation. Drug Deliv Transl Res., 2025; pp. 1\u201312. https:\/\/doi.org\/10.1007\/S13346-024-01767-8\/TABLES\/2.","DOI":"10.1007\/S13346-024-01767-8\/TABLES\/2"},{"issue":"3","key":"3386_CR151","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/S13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2021","unstructured":"\u0110or\u0111evi\u0107 S, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2021;12(3):500\u201325. https:\/\/doi.org\/10.1007\/S13346-021-01024-2.","journal-title":"Drug Deliv Transl Res"},{"issue":"3","key":"3386_CR152","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/S13346-020-00744-1","volume":"10","author":"MS Taha","year":"2020","unstructured":"Taha MS, Padmakumar S, Singh A, Amiji MM. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation. Drug Deliv Transl Res. 2020;10(3):766\u201390. https:\/\/doi.org\/10.1007\/S13346-020-00744-1.","journal-title":"Drug Deliv Transl Res"},{"key":"3386_CR153","unstructured":"European Medicines Agency (EMA), \u201cEudraCT Database,\u201d EU Clinical Trials Register. [Online]. Available: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search. Accessed 16 May 2025."},{"key":"3386_CR154","unstructured":"National Institute of Health (NIH), \u201cClinicalTrials.gov Online Database,\u201d ClinicalTrials.gov. [Online]. Available: https:\/\/clinicaltrials.gov\/. Accessed 16 May 2025."},{"issue":"3","key":"3386_CR155","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","volume":"10","author":"JM Metselaar","year":"2020","unstructured":"Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10(3):721\u20135. https:\/\/doi.org\/10.1007\/s13346-020-00740-5.","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"3386_CR156","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1208\/S12248-016-9961-7","volume":"18","author":"H Havel","year":"2016","unstructured":"Havel H, et al. Nanomedicines: from bench to bedside and beyond. AAPS J. 2016;18(6):1373\u20138. https:\/\/doi.org\/10.1208\/S12248-016-9961-7.","journal-title":"AAPS J"},{"key":"3386_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fbioe.2017.00069","volume":"5","author":"M Thomas","year":"2017","unstructured":"Thomas M, Willerth SM. 3-D bioprinting of neural tissue for applications in cell therapy and drug screening. Front Bioeng Biotechnol. 2017;5:1\u201311. https:\/\/doi.org\/10.3389\/fbioe.2017.00069.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"3386_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061750","volume":"15","author":"F Villanueva-Flores","year":"2023","unstructured":"Villanueva-Flores F, Garcia-Atutxa I, Santos A, Armendariz-Borunda J. Toward a new generation of bio-scaffolds for neural tissue engineering: challenges and perspectives. Pharmaceutics. 2023;15(6):1750. https:\/\/doi.org\/10.3390\/pharmaceutics15061750.","journal-title":"Pharmaceutics"},{"issue":"4\u20135","key":"3386_CR159","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/J.ADDR.2007.03.014","volume":"59","author":"SM Willerth","year":"2007","unstructured":"Willerth SM, Sakiyama-Elbert SE. Approaches to neural tissue engineering using scaffolds for drug delivery. Adv Drug Deliv Rev. 2007;59(4\u20135):325. https:\/\/doi.org\/10.1016\/J.ADDR.2007.03.014.","journal-title":"Adv Drug Deliv Rev"},{"key":"3386_CR160","doi-asserted-by":"publisher","DOI":"10.3346\/JKMS.2023.38.E56","author":"B Seo","year":"2023","unstructured":"Seo B, et al. Incidence and economic burden of adverse drug reactions in hospitalization: a prospective study in Korea. J Korean Med Sci. 2023. https:\/\/doi.org\/10.3346\/JKMS.2023.38.E56.","journal-title":"J Korean Med Sci"},{"key":"3386_CR161","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.120957","author":"J Sultana","year":"2013","unstructured":"Sultana J, Cutroneo P, Trifir\u00f2 G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013. https:\/\/doi.org\/10.4103\/0976-500X.120957.","journal-title":"J Pharmacol Pharmacother"},{"key":"3386_CR162","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41397-018-0053-1","volume":"19","author":"SL Chan","year":"2019","unstructured":"Chan SL, et al. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics J. 2019;19:401\u201310. https:\/\/doi.org\/10.1038\/s41397-018-0053-1.","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"3386_CR163","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.hlpt.2018.10.005","volume":"7","author":"H Kwon","year":"2018","unstructured":"Kwon H, Jung EY. The impact of policy on the growth of precision medicine. Health Policy Technol. 2018;7(4):347\u201357. https:\/\/doi.org\/10.1016\/j.hlpt.2018.10.005.","journal-title":"Health Policy Technol"},{"issue":"1","key":"3386_CR164","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/S40005-022-00607-6\/METRICS","volume":"53","author":"RK Thapa","year":"2023","unstructured":"Thapa RK, Kim JO. Nanomedicine-based commercial formulations: current developments and future prospects. J Pharm Investig. 2023;53(1):19\u201333. https:\/\/doi.org\/10.1007\/S40005-022-00607-6\/METRICS.","journal-title":"J Pharm Investig"},{"issue":"5","key":"3386_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS15051399","volume":"15","author":"R Tal\u00e9ns-Visconti","year":"2023","unstructured":"Tal\u00e9ns-Visconti R, de Juli\u00e1n-Ortiz JV, Vila-Bus\u00f3 O, Diez-Sales O, N\u00e1cher A. Intranasal drug administration in Alzheimer-type dementia: towards clinical applications. Pharmaceutics. 2023;15(5):1399. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15051399.","journal-title":"Pharmaceutics"},{"key":"3386_CR166","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.2147\/IJN.S117210","volume":"11","author":"DB Vieira","year":"2016","unstructured":"Vieira DB, Gamarra LF. Getting into the brain: liposome-based strategies for effective drug delivery across the blood\u2013brain barrier. Int J Nanomedicine. 2016;11:5381\u2013414. https:\/\/doi.org\/10.2147\/IJN.S117210.","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"3386_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1004472","volume":"22","author":"S Halbherr","year":"2025","unstructured":"Halbherr S, et al. Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: a single-center open-label clinical phase I trial (NEON trial). PLoS Med. 2025;22(5):e1004472. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1004472.","journal-title":"PLoS Med"},{"issue":"3","key":"3386_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14030574","volume":"14","author":"N Raina","year":"2022","unstructured":"Raina N, et al. Drug delivery strategies and biomedical significance of hydrogels: translational considerations. Pharmaceutics. 2022;14(3):574. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14030574.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3386_CR169","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4149\/neo_2018_180613N393","volume":"66","author":"I Karlsson","year":"2019","unstructured":"Karlsson I, et al. Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT. Neoplasma. 2019;66(2):288\u201393. https:\/\/doi.org\/10.4149\/neo_2018_180613N393.","journal-title":"Neoplasma"},{"key":"3386_CR170","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10158","author":"A Mandal","year":"2020","unstructured":"Mandal A, Clegg JR, Anselmo AC, Mitragotri S. Hydrogels in the clinic. Bioengineering & Translational Medicine. 2020. https:\/\/doi.org\/10.1002\/btm2.10158.","journal-title":"Bioengineering & Translational Medicine"},{"key":"3386_CR171","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi0069","author":"P Peruzzi","year":"2023","unstructured":"Peruzzi P, et al. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. Sci Transl Med. 2023. https:\/\/doi.org\/10.1126\/scitranslmed.adi0069.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3386_CR172","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/B:DRUG.0000006172.65135.3E\/METRICS","volume":"22","author":"C Guerin","year":"2004","unstructured":"Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs. 2004;22(1):27\u201337. https:\/\/doi.org\/10.1023\/B:DRUG.0000006172.65135.3E\/METRICS.","journal-title":"Invest New Drugs"},{"key":"3386_CR173","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jconrel.2021.06.007","volume":"335","author":"T Akita","year":"2021","unstructured":"Akita T, et al. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2. J Control Release. 2021;335:575\u201383. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.007.","journal-title":"J Control Release"},{"key":"3386_CR174","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejpb.2020.05.001","volume":"152","author":"T Kanazawa","year":"2020","unstructured":"Kanazawa T, Taki H, Okada H. Nose-to-brain drug delivery system with ligand\/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas. Eur J Pharm Biopharm. 2020;152:85\u201394. https:\/\/doi.org\/10.1016\/j.ejpb.2020.05.001.","journal-title":"Eur J Pharm Biopharm"},{"key":"3386_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00373","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM. Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. 2020. https:\/\/doi.org\/10.3389\/fnagi.2019.00373.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"3386_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01298-z","volume":"8","author":"Z-G Lu","year":"2023","unstructured":"Lu Z-G, et al. Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduct Target Ther. 2023;8(1):39. https:\/\/doi.org\/10.1038\/s41392-022-01298-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"3386_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101416","volume":"16","author":"AY Shchaslyvyi","year":"2023","unstructured":"Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current state of human gene therapy: approved products and vectors. Pharmaceuticals. 2023;16(10):1416. https:\/\/doi.org\/10.3390\/ph16101416.","journal-title":"Pharmaceuticals"},{"issue":"12","key":"3386_CR178","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122014","volume":"13","author":"R Bajracharya","year":"2021","unstructured":"Bajracharya R, Caruso AC, Vella LJ, Nisbet RM. Current and emerging strategies for enhancing antibody delivery to the brain. Pharmaceutics. 2021;13(12):2014. https:\/\/doi.org\/10.3390\/pharmaceutics13122014.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3386_CR179","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1474-4422(07)70326-5","volume":"7","author":"E Neuwelt","year":"2008","unstructured":"Neuwelt E, et al. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008;7(1):84\u201396. https:\/\/doi.org\/10.1016\/S1474-4422(07)70326-5.","journal-title":"Lancet Neurol"},{"key":"3386_CR180","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01717-z","author":"SU Rawal","year":"2022","unstructured":"Rawal SU, Patel BM, Patel MM. New drug delivery systems developed for brain targeting. Drugs. 2022. https:\/\/doi.org\/10.1007\/s40265-022-01717-z.","journal-title":"Drugs"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03386-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:51:19Z","timestamp":1780390279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03386-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":180,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3386"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03386-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"128"}}